ライフサイエンスコーパス: retroviral

1 that no major vertebrate lineage has escaped retroviral activity and that retroviruses are extreme ho

2 In mouse models of retroviral AML transplantation, as well as in retrospect

3 uce mutational signatures in targets such as retroviral and cancer cell genomes.

4 horylation on the activity of YY1-responsive retroviral and cellular promoters.

5 t binding protein 1 (PTBP1) shields specific retroviral and cellular transcripts from NMD.

6 Using retroviral and transgenic approaches to label adult-gene

7 re is consistent with previous reports using retroviral approaches that have revealed that a mature p

8 ved, which enhances current knowledge of the retroviral assembly pathway.

9 ences will provide greater insights into the retroviral assembly pathway.

10 appaB activity, especially in the context of retroviral assembly.

11 etroviral fate mapping, and lineage-specific retroviral barcode labeling, we find that clonally relat

12 ansfers into nonmanipulated mice, as well as retroviral barcoding, indicated that thymic dendritic ce

13 By combining retroviral-based multicolor clonal analysis with live im

14 ally prolonged survival in a murine model of retroviral BCR-ABL-driven CML and impaired the in vivo s

15 A dual-virus tracing strategy combining retroviral birthdating with rabies virus-mediated putati

16 IX to function in cytokinetic abscission and retroviral budding, but not in multivesicular body sorti

17 ects host genome integrity by disrupting the retroviral capsid as it transports viral nucleic acid to

18 omoting the abortive disassembly of incoming retroviral capsid cores; as a result, the retroviral gen

19 a retrovirus with a host cell membrane, the retroviral capsid is released into the cytoplasm of the

20 c manner by binding to and destabilizing the retroviral capsid lattice before reverse transcription i

21 uitin (Ub) ligase that assembles on incoming retroviral capsids and induces their premature dissociat

22 ng has been provided by structural models of retroviral capsids, it is unknown whether it may occur t

23 pha to accommodate the variable curvature of retroviral capsids.

24 ssary to recognize divergent and pleomorphic retroviral capsids.

25 We provide evidence that the associated retroviral capture event most probably occurred >100 Mya

26 ected cells, providing better tools to study retroviral cell-mediated infection.

27 nal fertilization has a pronounced effect on retroviral colonization of host genomes.

28 The retroviral cyclin (RV-cyclin) represents a highly select

29 Previous work showed that the retroviral cyclin (RV-cyclin), encoded by WDSV, has sepa

30 nario suggests a role for cell-free virus in retroviral disease progression.

31 sgene in order to study how tetherin affects retroviral dissemination and on which cell types its exp

32 tion and direct cell-to-cell transmission to retroviral dissemination and pathogenesis are unknown.

33 ological advances to infer broad patterns in retroviral diversity, evolution, and host-virus relation

34 ion and contrasting ERV diversity with known retroviral diversity, our study provides a cohesive fram

35 since the existence of an integrated form of retroviral DNA (the provirus) was first proposed by Howa

36 Thus, retroviral DNA increased translation of cointroduced gen

37 Herein we review the molecular mechanism of retroviral DNA integration, with an emphasis on reaction

38 des new insight into the structural basis of retroviral DNA integration.

39 n given the anticancer drug gefitinib or the retroviral drug atazanavir, the Por-deleted humanized PI

40 Despite the success of potent anti-retroviral drugs in controlling human immunodeficiency v

41 subset of transposable elements, endogenous retroviral elements (ERVs) containing long terminal repe

42 , ZSCAN4, KDM4E and PRAMEF-family genes) and retroviral elements (MERVL/HERVL family) that define the

43 Although many of these retroviral elements have lost their ability to replicate

44 vant to all transposable elements, including retroviral elements like HIV-1, which share with Mu the

45 tory function in reporter assays, identified retroviral elements with activating roles, and uncovered

46 NAs derived at least in part from endogenous retroviral elements, activation of the MDA5/MAVS RNA rec

47 ctivate tumour cell expression of endogenous retroviral elements, thus increasing intracellular level

48 ells offers a powerful experimental model of retroviral entry.

49 anscriptome and screened for the presence of retroviral env genes with a full-length ORF.

50 ia and Euarchontoglires, with the identified retroviral envelope gene encoding a full-length protein

51 ifferent evolutionary statuses of a captured retroviral envelope gene, with only syncytin-Opo1 being

52 Capture of retroviral envelope genes is likely to have played a rol

53 At variance with previously identified retroviral envelope genes, its encoding gene is found to

54 has been mapped to a conserved domain of the retroviral envelope glycoprotein of several exogenous as

55 chanism of immunosuppression mediated by the retroviral envelope glycoprotein.

56 Retroviral envelopes are known to be capable of elicitin

57 The retroviral enzyme integrase plays an essential role in t

58 IRT exhibits more slippage in vitro than the retroviral enzymes tested including that from HIV.

59 details of the structure and function of the retroviral enzymes-reverse transcriptase, protease, and

60 A retroviral etiology for malignant neoplasias in koalas h

61 By capturing the mode and pattern of retroviral evolution and contrasting ERV diversity with

62 Conversely, retroviral expression in murine Mincle-deficient DC reve

63 Enforced retroviral expression of Dusp9 in mouse GM-CSF-induced c

64 e used unbiased, high-throughput cloning and retroviral expression of individual pre-selection TCRs t

65 in complex II, all of which were rescued by retroviral expression of wild-type FOXRED1.

66 and retroviral genes coordinately, such that retroviral expression patterns can serve as markers of E

67 tor) enhances viral infectivity through anti-retroviral factor apolipoprotein B mRNA editing enzyme c

68 ental importance of SERINC5 as a potent anti-retroviral factor.

69 S2 shares no sequence homology with other retroviral factors known to counteract SERINC5.

70 Utilizing a combination of genetics, retroviral fate mapping, and lineage-specific retroviral

71 s discovery closes the last major gap in the retroviral fossil record and provides important insights

72 n lattice on the host's plasma membrane, the retroviral Gag polyprotein triggers formation of the vir

73 The retroviral Gag protein exhibits extensive amino acid seq

74 Previously, no retroviral Gag protein has been highly purified in milli

75 The capsid domain (CA) of the retroviral Gag protein is a primary determinant of Gag o

76 Many retroviral Gag proteins contain PPXY late assembly domai

77 underlying membrane binding and assembly of retroviral Gag proteins into a lattice are understood.

78 ogenesis, delineated mechanisms that control retroviral gene expression, and elucidated critical deta

79 crucial factor in leukemogenic potential of retroviral gene therapy and underscore the importance of

80 Retroviral gene therapy has proved efficacious for multi

81 ion of therapeutic transgene expression from retroviral gene therapy vectors by epigenetic defence me

82 Previous attempts using retroviral gene transfer to correct murine CD40L express

83 y believed that intasomes derived from other retroviral genera use tetrameric integrase.

84 roviral vectors derived from three different retroviral genera.

85 ong representative retroviruses in the known retroviral genera.

86 ent protein) created from all representative retroviral genera: Alpharetrovirus, Betaretrovirus, Delt

87 Overall, our findings provide evidence that retroviral genes contribute to tumoral immunosurveillanc

88 on factors in ES cells control both host and retroviral genes coordinately, such that retroviral expr

89 By reconstructing the canonical retroviral genes, we identified patterns of adaptation c

90 ng retroviral capsid cores; as a result, the retroviral genome is unable to traffic to the nucleus, a

91 on of HIV-1 is highly constrained, since the retroviral genome must contain a slippery sequence (sequ

92 ion of murine leukemia virus genomes but not retroviral genomes of the lentiviral or betaretroviral f

93 XT1 also facilitates the export of unspliced retroviral genomic RNA from simple type-D retroviruses s

94 MT generated 100-fold more beating iCMs than retroviral-GMT and shortened the duration to induce beat

95 transfer of SeV-GMT was more efficient than retroviral-GMT in reprogramming resident cardiac fibrobl

96 es and by motif searches in Human Endogenous Retroviral (HERV) RNA sequences.

97 In summary, our results indicate that retroviral host range extension is caused by spontaneous

98 offers the opportunity to induce protective retroviral immunity by restoration of retrovirus-specifi

99 We conclude that retroviral implementation of the CRISPR-Cas9 system is a

100 BP-associated factor plays a central role in retroviral infection and cancer development, and the C-t

101 ecretion is a powerful positive regulator of retroviral infection and that FMLV-IL-1beta represents a

102 TRIM5alpha inhibits retroviral infection by promoting the abortive disassemb

103 ugh the susceptibility of murine EC cells to retroviral infection has been extensively analyzed, few

104 amined the ability of TRIM5alpha to restrict retroviral infection in cells depleted of the autophagic

105 e requirements for control or elimination of retroviral infection remains an important aim.

106 esent a new therapeutic avenue to fight this retroviral infection, as it reestablishes the Th1/Th2 ba

107 domain proteins that have been implicated in retroviral infection, inflammation pathways, and cancer

108 ty is separable from the ability to restrict retroviral infection.

109 study the impact of inflammatory pathways on retroviral infection.

110 ta represents a new model of proinflammatory retroviral infection.

111 tors that may hold promise as treatments for retroviral infections and neurodegenerative disease.

112 proteins are restriction factors that block retroviral infections by binding viral capsids and preve

113 ogenous retroviruses (ERVs), the remnants of retroviral infections in the germ line, occupy ~8% and ~

114 related to exogenous retroviruses, represent retroviral infections of the deep past, and their abunda

115 retroviruses (ERVs) are remnants of ancient retroviral infections, and comprise nearly 8% of the hum

116 us retroviruses (ERVs), derived from ancient retroviral infections.

117 Several broadly neutralizing antibodies and retroviral inhibitors are currently being studied as pot

118 y labeled new granule cells at 7-8 days post retroviral injection (dpi) show that these cells respond

119 concerted strand transfer activity of delta-retroviral INs in vitro.

120 acute myeloid leukemias (AMLs) generated by retroviral insertional mutagenesis in Kras(G12D) "knocki

121 Yet, retroviral insertional mutagenesis screens identify RUNX

122 Here, we recruited retroviral insertional mutagenesis to obtain induction o

123 secondary genomic mutations, deletions, and retroviral insertions targeting B-lymphoid development,

124 tures highlight how HIV-1 can use the common retroviral intasome core architecture to accommodate dif

125 termine that the prototype foamy virus (PFV) retroviral intasome searches for an integration site by

126 Retroviral integrase (IN) functions within the intasome

127 Target-site selection by retroviral integrase (IN) proteins profoundly affects vi

128 dal interaction with chromatin and the gamma-retroviral integrase (IN).

129 Retroviral integrase catalyses the integration of viral

130 ucleophilic integration mechanism similar to retroviral integrases and transposases.

131 yield products similar to those generated by retroviral integrases and transposases.

132 The retroviral integrases are virally encoded, specialized r

133 new questions about the role of histones in retroviral integration and transcription.

134 The location of retroviral integration into the human genome is thought

135 Retroviral integration is catalysed by a tetramer of int

136 Retroviral integration proceeds via two integrase activi

137 these mutations occur in the same intron as retroviral integration sites in gene therapy-induced T-A

138 BET proteins guide gamma-retroviral integration to transcription start sites and

139 nd suggest that target site-selection limits retroviral integration.

140 ially informing future strategies to prevent retroviral integration.

141 ovo piRNA birth as host responds to a recent retroviral invasion.

142 Evidence for retroviral involvement was bolstered in 2000 by the isol

143 In mice, retroviral knockdown strategies against ATP6AP2, a recen

144 revious findings using thymidine analogs and retroviral labeling, thus providing an alternative appro

145 gh lineage tracking through the injection of retroviral libraries has long been the state of the art,

146 Using a retroviral library carrying over 100,000 genetic tags, w

147 d interneurons using a replication-defective retroviral library containing a highly diverse set of DN

148 Integration is a key feature of the retroviral life cycle.

149 ity and have functional implications for the retroviral life cycle.

150 ons of adenosine to inosine modifications in retroviral life cycles.

151 hylogenetic analyses suggest that this major retroviral lineage, and therefore retroviruses as a whol

152 ain known retroviruses, implying either that retroviral lineages are highly transient over evolutiona

153 Using an unbiased retroviral loss-of-function screen in nontransformed hum

154 a unique CpG-rich promoter not related to a retroviral LTR, with sites of expression including the p

155 s to characterize the interactions anchoring retroviral MA at the plasma membrane of infected cell.

156 In most retroviruses, retroviral MAs are N-terminally myristoylated.

157 ct shRNA (cshRNA) expression system based on retroviral microRNA (miRNA) gene architecture that uses

158 d we confirmed our results in a Friend virus retroviral model of infection in mice.

159 9), which is fully transforming in a murine retroviral model, in human cord blood cells.

160 Using a well-established retroviral model-avian Rous sarcoma virus (RSV)-we analy

161 In a retroviral mouse model performed in Mpl(-/-) mice, MPL P

162 mRNA, and it also is essential for export of retroviral mRNAs with retained introns.

163 Both chemical and retroviral mutagenesis resulted in a significantly incre

164 ctor integration sites is also important for retroviral mutagenesis screens.

165 Retroviral nucleocapsid (NC) proteins are nucleic acid c

166 diselenobisbenzamides (DISeBAs) as novel HIV retroviral nucleocapsid protein 7 (NCp7) inhibitors.

167 Using transfected (retroviral oncogene or fluorescent reporter construct) r

168 ade substantial contributions in the area of retroviral oncogenesis, delineated mechanisms that contr

169 The retroviral oncoprotein Tax from human T-cell leukemia vi

170 Syncytins are genes of retroviral origin captured by eutherian mammals, with a

171 of the human genome consists of sequences of retroviral origin, a result of ancestral infections of t

172 Approximately 8% of the human genome is of retroviral origin.

173 Retroviral overexpression of Bcl-xL promoted survival, w

174 Here, we show that retroviral overexpression of NLRP12 suppressed RelB nucl

175 Retroviral overexpression of SOCS3 in HepG2 cells (HepG2

176 capsid core structure.IMPORTANCE Studies of retroviral particle core morphology have demonstrated a

177 was examined directly using HCV-pseudotyped retroviral particles (HCV-pp).

178 Retroviral particles assemble on the PM and bud from inf

179 trong expression in the uterine glands where retroviral particles can be detected-plausibly correspon

180 The assembly of immature retroviral particles is initiated in the cytoplasm by th

181 IV-1 infection and cancer, HK2 genes produce retroviral particles that appear to be infectious, yet t

182 cell line presented AH1, a common endogenous retroviral peptide.

183 y pacidamycin moiety with the synthetic anti-retrovirals, presents a potential opportunity for the ut

184 used to test tRNA m(1)A58 MTase's impact on retroviral priming and transcription.

185 uman development proceeds in the presence of retroviral products.

186 This study highlights the malleability of retroviral protease folding pathways by illustrating how

187 indicating that complex interactions between retroviral proteins and host factors can fine-tune pathw

188 Our results allowed us to characterize 4 new retroviral proteins for the first time.

189 ns (MAs) play a key role in the transport of retroviral proteins inside infected cells and in the int

190 opies of intact open reading frames encoding retroviral proteins.

191 icken embryos, we used replication-competent retroviral RCAS vector system to generate transgenic chi

192 has suggested that xenotropic and polytropic retroviral receptor 1 (XPR1) might be involved in this p

193 th PFBC mutations in XPR1, a gene encoding a retroviral receptor with phosphate export function.

194 Using retroviral recombination substrates, we found that RAG1

195 n defect in patient T cells were restored by retroviral reconstitution.

196 Integration is vital to retroviral replication and influences the establishment

197 important in enhancing our understanding of retroviral replication and pathogenesis, including that

198 stablish IL-1beta as a positive regulator of retroviral replication and suggest that targeting this p

199 leamine 2,3-dioxygenase 1 (IDO1) can inhibit retroviral replication by metabolite depletion while tri

200 cART is effective in stopping the retroviral replication cycle, but not in inhibiting clon

201 s in infected cells is a crucial step in the retroviral replication cycle.

202 ependent dNTP depletion is thought to impair retroviral replication in these cells, but the relations

203 examine the potential impact of IL-1beta on retroviral replication in vivo, I constructed a novel mo

204 To test whether IL-1beta secretion affects retroviral replication in vivo, I constructed a novel mu

205 tanding factors that limit transposition and retroviral replication is fundamentally important.

206 he two domains to face each other.IMPORTANCE Retroviral replication requires that some of the viral R

207 Proteases are essential for retroviral replication, and HIV-1 and HIV-2 proteases sh

208 Protease is essential for retroviral replication, and protease inhibitors (PI) are

209 whereas in non-cycling cells restrictive to retroviral replication, SAMHD1 activation is likely to b

210 s to interferon signaling and restriction of retroviral replication.

211 into host chromatin is the defining step of retroviral replication.

212 tempt to identify the global determinants of retroviral repression in pluripotent mammalian cells.

213 there is a strong correlation between TRIM5 retroviral restriction activity and the ability to activ

214 gues, each of which has potential for potent retroviral restriction activity, all activated AP-1 sign

215 s that the inhibition of autophagy abrogates retroviral restriction by TRIM5 proteins.

216 tetramerization is not likely to explain the retroviral restriction defect, and we hypothesize that e

217 ohydrolase SAMHD1 is a myeloid cell-specific retroviral restriction factor that can be inactivated by

218 hesus macaque TRIM5alpha (rhTRIM5alpha) is a retroviral restriction factor that inhibits HIV-1 infect

219 TRIM5alpha is an interferon-inducible retroviral restriction factor that prevents infection by

220 SAMHD1 functions as an important retroviral restriction factor through a mechanism relyin

221 cannot rule out a contribution of SAMHD1 to retroviral restriction in relatively non-permissive CNS

222 The contributions of SAMHD1 to retroviral restriction in the central nervous system (CN

223 Retroviral restriction is a complex phenomenon that, des

224 elationship between the dNTPase activity and retroviral restriction is not fully understood.

225 SAMHD1-mediated retroviral restriction is thought to result from the dep

226 Retroviral reverse transcriptase (RT) of Moloney murine

227 After the discovery of retroviral reverse transcriptase in 1970, there was a fl

228 nase that introduces lethal mutations during retroviral reverse transcription.

229 Here, we show how upstream sensing of retroviral reverse transcripts integrates with the downs

230 ed nucleotide sequences derived from the non-retroviral RNA bornavirus.

231 ecessors of retrotransposon, telomerase, and retroviral RTs as well as the spliceosomal protein Prp8

232 active site are surprisingly different from retroviral RTs but remarkably similar to viral RNA-depen

233 Retroviral (RV) expression of genes of interest (GOIs) i

234 We uncover ancient retroviral sags in over 20 mammals to reconstruct their

235 r a great diversity of ERVs, indicating that retroviral sequences are much more prevalent and widespr

236 on between K111 and K222 suggests that these retroviral sequences have been templates for frequent cr

237 Endogenous retroviral sequences provide a molecular fossil record o

238 ugh transcriptional activation of endogenous retroviral sequences.

239 Using retroviral shRNA knockdown, we have demonstrated that th

240 between two repressive pathways involved in retroviral silencing in mammalian cells.

241 Like other retroviral species, the Gag polyprotein of HIV-1 contain

242 the CA-NC connecting region differs between retroviral species.

243 Whether trans-infection contributes to retroviral spread in vivo remains unknown.

244 The retroviral structural protein Gag binds to the inner lea

245 The retroviral structural protein Gag has three major domain

246 Binding of the retroviral structural protein Gag to the cellular plasma

247 The Gag protein is the main retroviral structural protein, and its expression alone

248 Our findings underscore the importance of retroviral structural proteins for integration site sele

249 illustrating further structural diversity of retroviral structures.

250 tion in species with a gyrencephalic cortex, retroviral studies in the ferret and primate suggest tha

251 esviruses encode a gene with similarity to a retroviral superantigen gene (sag) of the unrelated mous

252 of EIAV as a determinant that also modulates retroviral susceptibility to SERINC5, indicating that EI

253 Typical acute retroviral syndrome (ARS) was defined as fever plus at l

254 tasomal core, previously observed in simpler retroviral systems, is formed between two IN tetramers,

255 subjects and those either treated with anti-retroviral therapy (ART) or untreated.

256 Combination anti-retroviral therapy (cART) has drastically improved the c

257 predicts the results of the Short Pulse Anti-Retroviral Therapy at Seroconversion (SPARTAC) trial.

258 but fell substantially after 2005 when anti-retroviral therapy became widely available.

259 IV-infected participants in the CNS HIV Anti-Retroviral Therapy Effects Research cohort.

260 SHIV infection differs from combination anti-retroviral therapy in that it facilitates the emergence

261 ration should be taken when choosing an anti-retroviral therapy regimen.

262 the SMART (Strategies for Management of Anti-Retroviral Therapy) trial, CD4/CD8 ratio, smoking, comor

263 s treated for 15 weeks with combination anti-retroviral therapy, beginning on day 3 after infection,

264 ich can then be eliminated by effective anti-retroviral therapy.

265 Host restriction factor TRIM5 inhibits retroviral transduction in a species-specific manner by

266 Targeted deletion of Pbx1 by retroviral transduction of Cre recombinase into Pbx2-def

267 TCF7 retroviral transduction opposes GZMB expression and the

268 in a luciferase reporter assay and following retroviral transduction.

269 Fibroblast-derived iNSC colonies silenced retroviral transgenes and reactivated silenced X chromos

270 nti-colon cancer drug irinotecan and an anti-retroviral used to treat HIV infection, 3'-azido-3'-deox

271 The data strengthen retroviral vaccine strategies aimed at eliciting NAbs th

272 fied with the human ADA cDNA (MND-ADA) gamma-retroviral vector after conditioning with busulfan (90 m

273 at contained CD34(+) cells transduced with a retroviral vector encoding the human ADA complementary D

274 mpts at gene therapy for WAS using a Upsilon-retroviral vector improved immunological parameters subs

275 the genome are filtered out, and then unique retroviral vector integration sites are determined based

276 Identifying retroviral vector integration sites is also important fo

277 se tabular format to allow rapid analysis of retroviral vector integration sites.

278 analyze next-generation sequencing data for retroviral vector integration sites.

279 analyze next-generation sequencing data for retroviral vector integration sites.

280 Here we used a retroviral vector to express an oncogene specifically in

281 ogous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30

282 Superinduction by the retroviral vector was not dependent on the cell type or

283 nce was codon optimized and expressed from a retroviral vector.

284 R) alpha- and beta-chains were cloned into a retroviral vector.

285 ibility of human EC cells to transduction by retroviral vectors derived from three different retrovir

286 Human T cells were transduced with retroviral vectors encoding for the human norepinephrine

287 uced bronchial epithelial BEAS-2B cells with retroviral vectors expressing KRAS(G12V) and monitored m

288 tment of AIDS and the utility of integrating retroviral vectors in gene therapy applications.

289 Transgenes were overexpressed from retroviral vectors in primary human keratinocytes.

290 refore, the analysis of integration sites of retroviral vectors is a crucial step in developing safer

291 Analyzing the integration profile of retroviral vectors is a vital step in determining their

292 ed into the T cells of a patient using gamma-retroviral vectors or other randomly integrating vectors

293 nces the infectivity of lentiviral and gamma-retroviral vectors pseudotyped with various envelope gly

294 We used retroviral vectors to express PML-RARA, RUNX1-RUNX1T1, o

295 The initial gamma-retroviral vectors, next-generation lentiviral vectors,

296 ing three reprogramming methods: integrating retroviral vectors, non-integrating Sendai virus and syn

297 tein, or stress responses in the presence of retroviral vectors.

298 nts using transgenes expression in EPCs from retroviral vectors.

299 cessory protein from EIAV is an example of a retroviral virulence determinant that independently evol

300 viral elements (EVEs) are sequences from non-retroviral viruses that are inserted into the mosquito g